New Drug Development：
Focus on immune cell therapies (CAR-T、ADCV、DC-CIK、CIK、GDT)treating cancers and umbilical mesenchymal stem cell treating myocardial infarction, stroke, COVID-19 and other major diseases.
1.Core Technology Platform：
(1).Chimeric Antigen Receptor (CAR-T)
■ Patented anti-HLA-Gchimeric antigen receptor, which turn the HLA-G induced inhibitor to active immune signal, and lead to tumor cell mediated cytotoxicity.
■ The HLA-G protein expression of a normal cell is extremely low, no dangerous side effects occur in CAR001 treatment.
■ Patented suicide gene of iCas9, which avoid the occurrence of side effects on the cancer patient; the use of small molecule drug of AP20187 help terminate cell drug CAR001 from cytotoxicity。
(2).Dendritic Cells (DC)
■ Ever Supreme had unique technology in isolating and developing cancer cells with specificity.
■ Technology on development of tumor-specific antigen.
■ low rejection and side effects.
■ Research team found that GBM patient with PD-1+/CD8+ratio lower than 0.21 has overall survival rate extended from 20 months to 60.97 months.
(3). Combined Therapy of Dendritic Cells and CIK Cells (DC-CIK)
■ Optimization of manufacturing process, DC and CIK can be co-cultured within two weeks.
■ Customized therapy, which does not affect therapy that the patient is already received, and provides much flexibility for treatment.
■ Patients who have received DC-CIK therapy for treating Stage IV hepatoma, tumor markers is maintained within normal range, no deterioration.
(4). Cytokine-Induced Killer (CIK) Cell
■ Contains NKT cells (CD3+ CD56+) and NK cells (CD3- CD56+) in combination.
■ Not restricted by major histocompatibility complex (MHC); when a patient is failed to retrieve the tumor tissues, CIK cells may be produced and carry out for effective cell therapy.
■ Except the use of Interleukin 2 (IL-2), unique process are applied to maintain tumor cell mediated cytotoxicity in culturing technology。
■ Effective cytotoxicity of CIK cell on GBM cells. (Note：Data from Ever Supreme R&D)。
(5).Gamma Delta T (GDT) Cells
GDT cells attack cancer cells by identifying multiple antigen, including transmembrane protein, cell adhesion molecules, and compounds in the frequently-seen cancer cells (Isopentenyl pyrophosphate IPP).
2.Stem Cell Technology Platform：
(1).Allogenic Umbilical Mesenchymal Stem Cells (UMSC) treatment of Acute Myocardial infarction(AMI).
(2).Allogenic Umbilical Mesenchymal Stem Cells (UMSC) treatment for Stroke.
(3). Allogenic Umbilical Mesenchymal Stem Cells for Treating COVID-19
Product licensing, Joint-Venture, Strategic Alliance, Sales & Distribution
Booth No. M804